Last reviewed · How we verify
FLOVENT 250mcg
FLOVENT 250mcg is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved. Also known as: FP 250.
At a glance
| Generic name | FLOVENT 250mcg |
|---|---|
| Also known as | FP 250 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
- Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB) (PHASE4)
- Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma (PHASE4)
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (PHASE4)
- SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (PHASE4)
- A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLOVENT 250mcg CI brief — competitive landscape report
- FLOVENT 250mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about FLOVENT 250mcg
What is FLOVENT 250mcg?
FLOVENT 250mcg is a Small molecule drug developed by GlaxoSmithKline.
Who makes FLOVENT 250mcg?
FLOVENT 250mcg is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
Is FLOVENT 250mcg also known as anything else?
FLOVENT 250mcg is also known as FP 250.
What development phase is FLOVENT 250mcg in?
FLOVENT 250mcg is FDA-approved (marketed).
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Also known as: FP 250
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing